Background: People who inject drugs (PWIDs) and who are living with HIV and hepatitis C virus (HCV) infection are vulnerable to a range of health-related harms, including liver cirrhosis, hepatocellular carcinoma, and death. There is limited evidence describing how HIV serostatus shapes access to a physician for regular HCV care among PWID. Methods: Using generalized estimating equations, we examined the relationship between HIV-seropositivity and having access to a physician for regular HCV care. We conducted a mediation analysis to examine whether this association was mediated by increased frequency of engagement in health care.
INTRODUCTION
The advent of highly active antiretroviral therapy (HAART) has led to significant reductions in HIV-related morbidity, mortality, and viral transmission. [1] [2] [3] [4] [5] However, hepatitis C virus (HCV)-related complications have emerged as a greater relative contributor to disease burden among dually infected individuals. 5 Globally, an estimated 170 million individuals are chronically infected with HCV, 6 of which one-third experience progression to liver fibrosis and cirrhosis over a 20-30 year period. 7 Moreover, an estimated 700,000 deaths each year are attributable to HCV-related complications. 8 Because of shared transmission pathways, recent data suggest that approximately 3%-12% of the 36.9 million people living with HIV are coinfected with HCV. 9 Among people living with HIV who inject drugs, the prevalence of HCV coinfection is significantly higher, with estimates ranging between 50% and 90%. 5 The HIV Treatment as Prevention (TasP) initiative aims to scale-up access to HAART, dramatically curbing morbidity, mortality, and HIV transmission. 3 Endorsed by the UNAIDS 90-90-90 campaign, 10 TasP's efficacy and effectiveness has become increasingly apparent among marginalized populations. Encouragingly, there seem to be broader implications in the context of HCV coinfection. 3 The impact of increased engagement in health care on access to HCV care remains largely unexplored.
The advent of direct-acting antivirals (DAAs) for the treatment of HCV infection has resulted in remarkable improvements in rates of sustained virologic response across all genotypes and among various populations, including people who inject drug (PWID). Unfortunately, access and uptake of DAA therapy among PWID remains very low. 11 A growing body of literature indicates a number of barriers, including patient concerns over possible side effects, high cost of DAAs based therapy, fractured social networks, unstable housing, incarceration, and limited engagement in health care. 12, 13 Furthermore, these factors may be coupled with reluctance on the part of health care professionals to initiate DAAs in active PWID because of concerns over HCV reinfection. 14, 15 It is noteworthy that this reluctance may be partially attributed to historical HCV treatment guidelines which have traditionally excluded PWID. 12, 16 Understanding the multifaceted nature of barriers to DAA access among PWID will facilitate treatment scale-up. Although a growing body of literature has explored the patterns and correlates of HAART and DAA accessibility among PWID, 17, 18 potential differences between DAA treatment and care among HIV-positive and HIV-negative individuals remain unclear. 19 Thus, in a setting where there are no financial barriers to HIV treatment and care, and where universal access to DAA treatment is occurring, 20 the objective of this study was to assess the effect of HIV serostatus on accessing HCV physician care among PWID in Vancouver, Canada.
METHODS

Study Design and Population
Data for this study were drawn from the Vancouver Injection Drug Users Study (VIDUS), the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the At-Risk Youth Study (ARYS), 3 prospective cohorts involving people who use illicit drugs in Vancouver, Canada. The methods for these studies have been described elsewhere. [21] [22] [23] [24] [25] To be eligible for VIDUS, participants must be 18 years or older and report injection drug use at least 1 month before enrollment. ACCESS participants must be 18 years or older and report using an illicit drug (other than or in addition to cannabis) in the month before enrollment. ARYS participants must be 14-26 years of age, street-involved, and report using an illicit drug (other than or in addition to cannabis) in the month before enrollment. Recruitment was conducted through self-referral, street outreach, and snowball sampling.
The data collection instruments and procedures were harmonized across the 3 cohorts to allow for pooled analyses. At baseline and semiannually, participants completed an interviewer-administered questionnaire that elicited information on sociodemographic characteristics, drug use patterns, and other relevant exposures and outcomes. In addition, at each visit, participants provided blood samples for HIV and HCV serologic tests and HIV disease monitoring as appropriate. If participants are tested positive for HIV and/or HCV, which are reportable diseases, the study team provides posttest counseling and linkage to care. A $30 (CAD) honorarium was offered to participants on completion of each study visit. All 3 cohorts have received ethical approval by the University of British Columbia/Providence Health Care Research Ethics Board.
Study Sample
For the present analysis, the sample was restricted to those who: (1) were HCV-positive at baseline or those who seroconverted between September 2005 and May 2015; (2) completed at least 1 follow-up visit after the positive HCV test result; (3) tested positive for HCV and reported a history of injection drug use during the same visit; (4) had chronic HCV, defined as not having spontaneously cleared HCV (ascertained through self-report); and (5) did not die during the study period (or up until the date of death confirmed through BC's Vital Statistics database). For participants added to the sample during follow-up (ie, those who HCVseroconverted during follow-up), their data after seroconversion were included.
Variable Selection
The primary outcome of interest was access to a physician for regular HCV care, defined by any self-reported access to a doctor or a specialist for regular HCV care at least once in the past 6 months. We felt that it was important to examine HCV care more broadly, including both access to primary care and specialist physicians given that in BC, treatment guidelines indicate that both practitioner types are allowed to prescribe DAA-based treatments. We did not restrict to treatment access given that fibrosis level restrictions to prescribing DAAs likely limited treatment availability during the study period. Regardless, HCV care linkage remains an important outcome measure. The primary explanatory variable was HIV-seropositivity, defined as a positive HIV antibody test. We also considered a selection of possible confounders, including: age (per year increase); sex (male vs. female); homelessness (yes vs. no); incarceration (yes vs. no); $daily opioid injection drug use (yes vs. no); $daily stimulant injection drug use (yes vs. no); enrollment in methadone maintenance therapy (yes vs. no); and hospitalized (yes vs. no). The potential mediator variable (frequency of engagement in health care) was defined as having had access to a doctor, clinic, specialist, jail doctor, health care outside hospital/clinic/doctor's office, or other in the past 6 months (once vs. once every 2-3 months vs. once a month vs. every 1-2 weeks vs. .once a week vs. no access). All variables except age and sex were considered as time-updated variables of events reported in the 6 months before interview.
Statistical Analyses
As a first step, we examined descriptive and sociodemographic characteristics of the sample, stratified by having had access to a physician for regular HCV care at least once during the study period. Next, we used bivariable generalized estimating equations (GEEs) with logit link function and exchangeable working correlation structure to estimate the relationship between the outcome (ie, access to a physician for regular HCV care) and all explanatory variables, including HIV-seropositivity. Then, a multivariable GEE model was constructed where all secondary variables significant at P ,0.05 in bivariable analyses were included.
Multicollinearity was also assessed using the variance inflation factor.
As a secondary analysis, we implemented methods developed by Imai et al 26 to explore whether the association of interest was mediated by an increased frequency of engagement in health care. To begin, we transformed our categorical variable (frequency of engagement) into a numeric variable (ie, once every 6 months = 1, once every 2-3 months = 2, once a month = 3, every 1-2 weeks = 4, .once a week = 5, and no access = 0), to estimate the overall mediation effect. Parameters of interest included: the Average Casual Mediation Effect (ACME), defined as the average mediated effect between the predictor (HIV-seropositivity) and the outcome through mediator (frequency of access); the Average Direct Effect (ADE), defined as the ADE of the predictor on the outcome; the Total Effect (TE), which was the entire effect the predictor had on the outcome (ie, ACME + ADE); and the Proportion Mediated, which was the proportion of the causal effect of independent variable that was mediated by the mediator (ie, ACME/TE). Averaged effects were calculated over 50 iterations. Finally, a sensitivity analysis was used to identify the value of rho at which ACME = 0, which is the correlation between the error terms of the mediator and outcome models. Essentially, the sensitivity analysis was used to probe the plausibility of sequential ignorability. Statistical significance was defined at the 0.05 level. All analyses were performed in RStudio version 0.99.892 (Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline descriptive and sociodemographic characteristics, stratified by the outcome are presented in Table 1 . Of the 1627 participants eligible for inclusion, 582 (35.8%) were HIV-positive at baseline and an additional 31 (1.9%) became HIV-positive during follow-up. Five hundred seventy-three (35.2%) were female and the median age at baseline was 41 years [interquartile range: 47.4-33.5 = 13.9 years]. Overall, participants contributed a total of 9212 person-years of follow-up. Of the 1627 participants, 943 (58.0%) were engaged in health care at least once a month and 274 (16.8%) reported no access to care. Of the 1357 participants with access to a physician for regular HCV care at least once during the study period, 1161 reported access at baseline, and 525 (38.7%) were HIV-seropositive.
As presented in Table 2 , in bivariable analyses, HIV serostatus was significantly and positively associated with access to a physician for regular HCV care [odds ratio (OR) = 2.17; 95% confidence interval (CI): 1.93 to 2.44]. This association remained largely unchanged in multivariable analysis even after adjusting for a range of possible confounders [adjusted OR = 1.99; 95% CI: 1.77 to 2.24].
Mediation analysis yielded a statistically significant ACME Approximately 26% of the effect was attributable to mediation. As a sensitivity analysis, the mediation analysis was repeated using baseline (first available) follow-up data and results were largely unchanged (data not shown). The value of r at which ACME would be zero was 0.2. Although this value indicates a seemingly low magnitude of hidden bias because of unobserved confounders, it cannot be calibrated in conjunction with results from studies of a similar construct, which leaves the mediatoroutcome association indeterminate.
DISCUSSION
In this study, we observed a high proportion of participants who reported access to a physician for regular HCV care. We also found a positive and independent relationship between HIV-seropositivity and access to a physician for regular HCV care among PWID, after adjusting for various confounders. In addition, our findings revealed that an increased frequency of engagement in health care mediated this relationship.
Traditionally, PWID were among the least likely to have access to HCV care. 13, 27 Encouragingly, our findings suggest a marked shift in HCV care accessibility among coinfected PWID, with 242 (39.48%) of coinfected participants who reported having had access to regular HCV physician care at baseline in the past 6 months. Of 613 coinfected participants, 554 (90.4%) reported access to a physician for regular HCV care at least once during the study period. It is important to note that although there have been guideline changes to increase accessibility to HCV treatment, DAAs were not covered as part of the PharmaCare drug coverage program until 2015, which took place after the study period. Similarly to other countries that have moved toward universal coverage for HCV medications, 28 in April 2017, the BC government expanded DAA coverage to HIV/HCV-coinfected individuals regardless of liver disease severity, and committed to provide universal DAA coverage for all BC residents with chronic HCV infection starting in early 2018. 29 Future research should seek to assess the impact of policy change on uptake of HCV treatment and care among this population.
That HIV-seropositive PWID were more likely to engage in HCV care, may be partially attributable to HIV care facilities which are operating under an integrated care model. 30 Previous research has demonstrated the importance of integrated care models on mitigating barriers to HCV care for HIV-seropositive populations. For example, a recent retrospective review of HIV/HCV-coinfected patients in New York found that HCV therapy can be safely integrated into HIV primary care settings with encouraging sustained virologic response rates (92%). 31 Similarly, Brunner et al demonstrated the feasibility of offering HCV and HIV care within opioid agonist treatment (OAT) programs. This integrated "one-stop-shop" approach yielded HCV treatment outcomes comparable with those in nondrug using populations. 32 In fact, a true "one-stop-shop" approach will also be pursuant to reducing frequency of health care engagement; lessening wasteful time, resources, and spending. 33 In response, a number of international health organizations have recommended the integration of infectious disease (eg, HIV, HCV, and HBV) testing, treatment, and care among individuals with comorbid conditions. 34, 35 Accordingly, the implementation of integrated care models for HIV/HCV-coinfected PWID should be considered globally. [34] [35] [36] That HIV-seronegative PWID were less likely to engage in HCV care reinforces an urgent need to look beyond conventional approaches to health care delivery. Similarly to what was proposed previously, the integration of OAT and HIV-related services impacts positively on access to HIV care, adherence, and health outcomes, and this approach has been endorsed by the World Health Organization. 37, 38 A growing body of evidence positions the integration of OAT-and HCV-related services as an advantageous undertaking in part, given its ability to remove barriers to HCV care among individuals who do not seek traditional health care services. 39, 40 The availability of HCVrelated services within OAT clinics eliminates the requirement for referrals to an HCV specialist and allows for the provision of immediate patient care. 40 Other successful lowthreshold models of HCV care include health care delivery through community-based clinics, peer-based models of treatment, and task shifting. 41, 42 Researchers should seek to explore the impact of these diverse and innovative delivery strategies to improve uptake of HCV care for HCVmonoinfected PWID.
Our study had several limitations. First, although HIV/ HCV results were ascertained by laboratory assays, measurement of the outcome and confounder variables was reliant on self-reported data, which is susceptible to social desirability and recall bias. Second, despite adjusting models for known confounders, results may be subject to underlying residual and unmeasured confounding. Third, because of the observational nature of the VIDUS, ACCESS, and ARYS studies, we were unable to definitively establish causation. Finally, this is a nonrandom sample that is not representative of a larger population and therefore, the extent to which these results may be generalized beyond our sample is unclear.
Overall, our findings demonstrate an essential need for scaling-up equitable access to HCV therapies, with services delivery models tailored to the needs of PWID. A sustained commitment to address these contextual differences will be essential to mitigate the alarming rates of preventable HCVrelated morbidity and mortality experienced among PWID.
